Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 pCR is related to combination of CYP1B1 and ERCC1 polymorphisms

From: ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors

CYP1B1 (Leu432Val) ERCC1 (Asn118Asn) N pCR OR 95% CI P value
n %a
CC TT 19 2 10.5 1 Reference  
CC CT 22 11 50.0 8.5 (1.6–46) 0.013
CC CC 6 1 16.7 1.7 (0.13–23) 0.69
CG TT 15 1 6.7 0.61 (0.05–7.4) 0.70
CG CT 20 2 10.0 0.94 (0.12–7.5) 0.96
CG CC 10 2 20.0 2.1 (0.25–18) 0.49
GG TT 6 1 16.7 1.7 (0.13–23) 0.69
GG CT 8 3 37.5 5.1 (0.66–39) 0.12
GG CC 7 2 28.6 3.4 (0.38–31) 0.28
  1. Significant results are shown in italic.
  2. pCR pathological complete response.
  3. a Percentages of evaluable patients.